A biotechnology company developing molecular-based diagnostic, prognostic, and predictive medical tests designed to help healthcare practitioners treat cancer.
On January 21, 2016 Biotheranostics completed a private equity round with $32 million in funding from MVM Life Science Partners (lead investor), HealthQuest Capital, and Canepa Healthcare.